Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients.
The amount of transfused dimethyl sulfoxide (DMSO) is indicated as the major cause of the cryoprotectant-related toxicity in autologous stem cell recipients, with a high incidence of major cardiac side effects. In this study we tried to discover whether fractionated infusion of the total graft volume could prevent the DMSO-related major cardiovascular side effects. We conclude that continuous cardiac monitoring during and after fractionated infusions of DMSO-containing graft documented no major arrhythmias, with only seven episodes of asymptomatic sinus bradycardia.
Dipartimento di Emato-Oncologia, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
M
M
Martino
F
F
Morabito
G
G
Messina
G
G
Irrera
G
G
Pucci
P
P
Iacopino
D000293:Adolescent; D000328:Adult; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000517:prevention & control*; D005591:Chemical Fractionation; D015925:Cryopreservation; D004121:Dimethyl Sulfoxide / Q000009:adverse effects*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D014182:Transplantation, Autologous
D004121:Dimethyl Sulfoxide